-
1 week ago | 
urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt
OpinionVideoJune 20, 2025Author(s):,Panelists discuss the promising results of the BOND-3 trial evaluating intravesical cretostimogene for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting its high complete response rates, favorable safety profile, and potential to offer an effective, bladder-sparing alternative without the toxicity of systemic immunotherapy.
-
1 week ago | 
urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt
OpinionVideoJune 20, 2025Author(s):,Panelists discuss emerging immunotherapy strategies for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), particularly the combination of BCG with systemic checkpoint inhibitors, noting promising response rates but significant toxicity concerns that currently limit widespread adoption to select high-risk patients, pending further trial data and safety protocol development.
-
2 weeks ago | 
urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt
OpinionVideoJune 13, 2025Author(s):,Panelists discuss current FDA-approved treatments for BCG-unresponsive carcinoma in situ, noting varying response rates among pembrolizumab, nadofaragene, and BCG combined with IL-15 superagonist, while highlighting promising investigational combination immunotherapies like oncolytic viruses and checkpoint inhibitors that may improve outcomes in this challenging patient population.
-
2 weeks ago | 
urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt
OpinionVideoJune 13, 2025Author(s):,Panelists discuss emerging data comparing bladder-sparing therapies to radical cystectomy in BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting the nuanced trade-offs in oncologic outcomes and quality of life, and emphasizing the need for shared decision-making as prospective studies like CISTO refine patient selection for personalized treatment strategies.
-
2 weeks ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
OpinionVideoJune 12, 2025Author(s):,Panelists discuss how recent advancements in NMIBC treatment, including the approval of nadofaragene firadenovec, pembrolizumab, and intravesical therapies like TAR-200, have reshaped care for BCG-unresponsive patients, with promising developments and ongoing trials at AUA 2025 paving the way for more personalized and effective treatment strategies in the future.
-
2 weeks ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
OpinionVideoJune 12, 2025Author(s):,Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access barriers, ensuring that NMIBC patients receive timely access to novel treatments like nadofaragene firadenovec and pembrolizumab.
-
2 weeks ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
OpinionVideoJune 12, 2025Author(s):,Panelists discuss how overcoming challenges such as cost, insurance coverage, regulatory hurdles, patient selection, and the need for education is crucial for improving access to novel therapies like nadofaragene firadenovec and pembrolizumab, ultimately enhancing outcomes for NMIBC patients.
-
3 weeks ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how recent trials, including KEYNOTE-057, QUILT-3.032, and CORE-001, highlight the promising efficacy, durability, and manageable safety profiles of novel treatments like pembrolizumab, nogapendekin alfa inbakicept, and nadofaragene firadenovec, while also exploring the potential of combination therapies and novel intravesical options like TAR-200 and UGN-102 for improving outcomes in non–muscle-invasive bladder cancer (NMIBC).
-
3 weeks ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how the ongoing ABLE-32 and ABLE-41 trials are exploring the efficacy and safety of nadofaragene firadenovec in different NMIBC patient populations, with ABLE-32 focusing on intermediate-risk patients and ABLE-41 examining real-world effectiveness and safety. The ongoing clinical trials investigating nadofaragene firadenovec include the ABLE-32 and ABLE-41 trials, each focusing on different aspects of its use in treating non-muscle invasive bladder cancer (NMIBC).
-
4 weeks ago | 
urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt
Author(s):,Panelists discuss evolving strategies for managing non–muscle-invasive bladder cancer (NMIBC), highlighting how risk stratification, resource limitations, and emerging therapies like gemcitabine-docetaxel are shaping treatment decisions, while emphasizing the urgent need for predictive tools and biomarkers to guide personalized care. The current standard of care for non–muscle-invasive bladder cancer (NMIBC) is highly dependent on risk stratification.
